QGEN · CIK 0001015820
What QIAGEN N.V. told the SEC could break it.
Qiagen's disclosures cluster on the physical and regulatory footprint of making diagnostics across borders. Its production is concentrated at a single 986,000-square-foot owned site in Hilden, Germany (with a secondary U.S. facility in Maryland), and certain instrumentation components and chemicals come from only a single source, so a disruption at either point could cut into sales. Layered on top is policy exposure to the flow of goods — new import tariffs, including those tied to U.S.–China relations, dented 2025 gross profit, while in-vitro diagnostics now require separate UK certification post-Brexit alongside EU rules.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- new import tariffs (incl. U.S.–China trade)medium
New tariffs negatively impacted Qiagen's 2025 gross profit, and evolving trade policies/import duties — including those arising from U.S.–China relations — may create cost burdens, pricing pressure and supply chain instability.
“Shifts in trade policies, import duties, and tariff regimes, including those arising from evolving U.S.– China relations or regional policy actions, may create additional cost burdens or restrictions on the flow of goods, potentially affecting supply chain stability and market access.”
- IVD medical device regulation (UK MHRA post-Brexit / EU IVDR)low
Post-Brexit, Qiagen's in vitro diagnostics require separate UK (MHRA) certification with a UK Responsible Person, adding regulatory complexity alongside EU IVDR requirements for market access.
“According to MHRA, IVDs will require certification in the U.K., which is defined as England, Scotland and Wales, while companies will still be able to sell tests in Northern Ireland under existing EU IVD regulations.”
SEC filing →As of 2026
Geographic concentration
- primary manufacturing concentrated at Hilden, Germanymedium
Qiagen's largest facility — a 986,000 sq ft owned site at Hilden, Germany — handles manufacturing, warehousing, distribution and R&D, concentrating a large share of consumables production in Germany (with a secondary site in Germantown, Maryland).
“Facility location Country Purpose Owned or leased Square feet Hilden Germany Manufacturing, warehousing, distribution, research and development and administration Owned 986,000 Germantown, Maryland U.S.”
SEC filing →As of 2026
Sole-source dependency
- single-source instrumentation components and chemicalsmedium
Although Qiagen buys from many suppliers, key components of certain products — including certain instrumentation components and chemicals — are available only from a single source, and delays or interruptions could reduce sales.
“However, key components of certain products, including certain instrumentation components and chemicals, are available only from a single source. If supplies from these vendors were delayed or interrupted for any reason, we may not be able to obtain these materials timely or in sufficient quantities to produce certain products, and sales levels could be negatively affected.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“We procure certain reagents, equipment, chips/cards and other materials used to perform our tests from sole suppliers such as ThermoFisher Scientific, Inc., Promega and Qiagen, Inc. Some of these items are unique to these suppliers and vendors.”
Cited →“Qiagen N.V., which supplies us with a proprietary buffer reagent.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch